Skip to Content

Medibio Ltd MDBIF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialisation of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It primarily serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets, being Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.

100 Albert Road, Level 4
Melbourne, VIC, 3205, Australia
T +61 396927222
Sector Healthcare
Industry Health Information Services
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type Hard Assets
Employees 4